During the H1N1 outbreak in 2009, vaccines only became available in large quantities after the peak of human infections. This was a learning experience for vaccination companies.
In the context of the 2009 H1N1 pandemic, it took until the peak of human infections to produce enough vaccines for widespread distribution. This experience served as a valuable learning opportunity for vaccine companies.